Cognition Therapeutics, Inc.
NASDAQ:CGTX
0.4744 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.372 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.067 | 0.058 | 0.066 | 0.065 | 0.061 | 0.06 | 0.06 | 0.06 | 0.059 | 0.056 | 0.023 | 0.023 | 0.024 | 0.023 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.067 | -0.058 | 0.306 | -0.065 | -0.061 | -0.06 | -0.06 | -0.06 | -0.059 | -0.056 | -0.023 | -0.023 | -0.024 | -0.023 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.823 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.577 | 10.553 | 11.6 | 11.669 | 8.497 | 5.43 | 6.44 | 8.268 | 9.098 | 6.518 | 5.573 | 3.675 | 4.894 | 4.43 | 3.287 | 3.399 | 2.755 | 3.446 |
| General & Administrative Expenses
| 3.101 | 3.549 | 3.589 | 3.076 | 3.32 | 3.543 | 2.86 | 4.357 | 3.115 | 2.895 | 6.235 | 1.548 | 1.09 | 1.153 | 0.833 | 1.062 | 1.18 | 1.445 |
| Selling & Marketing Expenses
| -0.067 | -0.058 | -0.066 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.034 | 3.491 | 3.523 | 3.076 | 3.32 | 3.543 | 2.86 | 4.357 | 3.115 | 2.895 | 6.235 | 1.548 | 1.09 | 1.153 | 0.833 | 1.062 | 1.18 | 1.445 |
| Other Expenses
| 0.333 | 0.244 | 0.287 | 0.314 | 0.172 | -3.426 | -3.981 | -5.947 | -0.042 | -5.904 | -0.604 | -0.924 | -0.941 | 0.145 | 0.129 | 0.095 | 0.116 | 0.142 |
| Operating Expenses
| 14.611 | 14.044 | 15.123 | 7.061 | 4.892 | 5.547 | 5.319 | 6.678 | 5.828 | 3.509 | 6.736 | 2.186 | 1.338 | 0.891 | 1.411 | 1.269 | 1.254 | 2.618 |
| Operating Income
| -14.678 | -14.102 | -15.189 | -14.745 | -11.817 | -8.973 | -9.3 | -12.625 | -12.213 | -9.413 | -11.808 | -5.223 | -5.984 | -5.583 | -4.12 | -4.461 | -3.935 | -4.891 |
| Operating Income Ratio
| 0 | 0 | -40.831 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 7.637 | 4.951 | 7.048 | 0.314 | 0.172 | 2.801 | 4.118 | 6 | -0.042 | 5.7 | -0.604 | -0.924 | 0.205 | 1.651 | 0.072 | -0.016 | 0.02 | 0.388 |
| Income Before Tax
| -7.041 | -9.151 | -8.141 | -6.749 | -4.726 | -6.172 | -5.182 | -6.625 | -5.877 | -3.713 | -7.339 | -3.11 | -1.49 | 0.223 | -1.868 | -1.791 | -1.674 | -2.506 |
| Income Before Tax Ratio
| 0 | 0 | -21.884 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.015 | 2.297 | 0.316 | 0.178 | -2.791 | -16.154 | -6 | -0.125 | 0.125 | 0.387 | -0.924 | -0.584 | 0.682 | 0.658 | 0.601 | 0.556 | 0.418 |
| Net Income
| -7.041 | -9.151 | -8.141 | -6.749 | -4.726 | -3.381 | 10.972 | -0.625 | -5.752 | -3.838 | -7.339 | -3.11 | -1.49 | 0.223 | -1.868 | -1.791 | -1.674 | -2.506 |
| Net Income Ratio
| 0 | 0 | -21.884 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.18 | -0.27 | -0.26 | -0.22 | -0.16 | -0.12 | 0.38 | -0.027 | -0.25 | -0.17 | -0.35 | -0.15 | -0.071 | 0.01 | -0.089 | -0.084 | -0.077 | -0.12 |
| EPS Diluted
| -0.18 | -0.27 | -0.26 | -0.22 | -0.16 | -0.12 | 0.38 | -0.027 | -0.25 | -0.17 | -0.35 | -0.15 | -0.071 | 0.01 | -0.089 | -0.084 | -0.077 | -0.12 |
| EBITDA
| -14.611 | -14.044 | -15.123 | -6.682 | -4.659 | -6.102 | -5.112 | -6.563 | -5.811 | -3.648 | -7.317 | -3.087 | -2.255 | -0.723 | -1.258 | -1.15 | -1.113 | -2.451 |
| EBITDA Ratio
| 0 | 0 | -40.653 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |